Directed Migration of Smooth Muscle Cells to Engineer Plaque-Resistant Vein Grafts

Abstract

Purpose:

To test the hypothesis that controlled perivascular release of tissue plasminogen activator (tPA) can generate cleaved extracellular matrix (ECM) chemotactic gradients to guide the migration of vascular smooth muscle cells (SMCs) away from the lumen, thereby limiting neointima formation.

Methods:

This hypothesis was tested in rabbit models in which the perivascular surface of vein bypass grafts was treated with microspheres releasing tPA (MS-tPA), microspheres containing no drug (MS-blank), or phosphate buffered saline (PBS). Vein graft segments harvested after 7 days were then evaluated for elastin content, proliferating SMCs, intima-to-media (I/M) ratio, and inflammation; late impact on neointima formation was also examined.

Results:

The 7-day results demonstrated cleaved elastin gradients and proliferating SMCs that assumed a more peripheral distribution in the MS-tPA group than MS-blank and PBS controls (p < 0.05). At 28 days, vein grafts treated with MS-tPA showed a mean I/M ratio (0.35±0.04) that was 63.5% lower than PBS controls (0.96±0.07, p < 0.005) and 43.5% lower than MS-blank specimens (0.62±0.08, p < 0.05).

Conclusions:

Perivascular release of tPA modifies ECM gradients, directionally guides SMC migration away from the lumen, and limits neointima formation.

Keywords

rabbit model neointima tissue plasminogen activator saphenous vein graft extracellular matrix smooth muscle cells tissue engineering

Get full access to this article

View all access options for this article.

References

Tardif

Cote

Lesperance

. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997; 337: 365–372.

Motwani

Topol

. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation. 1998; 97: 916–931.

Allaire

Clowes

. Endothelial cell injury in cardiovascular surgery: The intimal hyperplastic response. Ann Thorac Surg. 1997; 63: 582–591.

Casscells

. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation. 1992; 86: 723–729.

Libby

Tanaka

. The molecular bases of restenosis. Prog Cardiovasc Dis. 1997; 40: 97–106.

Holifield

Helgason

Jemelka

. Differentiated vascular myocytes: Are they involved in neointimal formation? J Clin Invest. 1996; 97: 814–825.

Herdeg

Oberhoff

Baumbach

. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo. J Am Coll Cardiol. 2000; 35: 1969–1976.

Lee

Forster

Yeung

. Clinical applications of brachytherapy for the prevention of restenosis. Vasc Med. 1999; 4: 257–268.

Batchelor

Robinson

Strauss

. The extracellular matrix in balloon arterial injury: A novel target for restenosis prevention. Prog Cardiovasc Dis. 1998; 41: 35–49.

10.

Forough

Koyama

Hasenstab

. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996; 79: 812–820.

11.

Yoshida

Mitsumata

Ling

. Migration of medial smooth muscle cells to the intima after balloon injury. Ann N Y Acad Sci. 1997; 811: 459–470.

12.

Johnson

. TNK-tPA: A new thrombolytic for treatment of acute myocardial infarction. S D J Med. 2000; 53: 185–186.

13.

Skinner

Raines

Ross

. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol. 1994; 145: 1070–1081.

14.

Bingley

Campbell

Hayward

. Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann N Y Acad Sci. 1997; 811: 238–244.

15.

Ooyama

Fukuda

Oda

. Substratumbound elastin peptide inhibits aortic smooth muscle cell migration in vitro. Arteriosclerosis. 1987; 7: 593–598.

16.

Carmeliet

Moons

Ploplis

. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997; 99: 200–208.

17.

Liotta

Goldfarb

Brundage

. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981; 41: 4629–4636.

18.

Wilhelm

Pentland

. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA. 1989; 86: 2632–2636.

19.

Rabbani

Johnstone

Rudd

. PPACK attenuates plasmin-induced changes in endothelial integrity. Thromb Res. 1993; 70: 425–436.

20.

Hilfiker

Waugh

Li-Hawkins

. Enhancement of neointima formation with tissue-type plasminogen activator. J Vasc Surg. 2001; 33: 821–828.

21.

Yuksel

Weinfeld

Cleek

. De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: A novel concept and capability. Plast Reconstr Surg. 2000; 105: 1721–1729.

22.

Waugh

Li-Hawkins

Yuksel

. Thrombomodulin overexpression to limit neointima formation. Circulation. 2000; 102: 332–337.

23.

Celletti

Waugh

Amabile

. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001; 7: 425–429.

24.

Yuksel

Weinfeld

Cleek

. Increased free fat-graft survival with the long-term, local delivery of insulin, insulin-like growth factor-I, and basic fibroblast growth factor by PLGA/PEG microspheres. Plast Reconstr Surg. 2000; 105: 1712–1720.

25.

Elkins

Waugh

Amabile

. Development of a platform to evaluate and limit instent restenosis. Tissue Eng. 2002; 8: 395–407.

26.

Hinek

Boyle

Rabinovitch

. Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced “shedding” of the 67-kDa cell surface elastin binding protein. Exp Cell Res. 1992; 203: 344–353.

27.

Yuksel

Weinfeld

Cleek

. Augmentation of adipofascial flaps using the long-term local delivery of insulin and insulin-like growth factor-1. Plast Reconstr Surg. 2000; 106: 373–382.